OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused...

PCI Biotech to present at European Biotech Investor Days 2021 Oslo (Norway), 6 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that...

PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the...